NHWD-870   Click here for help

GtoPdb Ligand ID: 10743

Synonyms: NHWD870
Compound class: Synthetic organic
Comment: NHWD-870 is an orally bioavailable bromodomain and extra-terminal (BET) inhibitor, that exhibits selectivity for bromodomain containing 4 (BRD4) [2]. It was developed for anti-cancer potential. In vitro, it is more potent than clinical stage BET inhibitors such as birabresib (OTX-015) and molibresib (GSK-525762). NHWD-870 potently reduces tumour growth in a number of different mouse models of cancers, including lung and ovarian tumours, lymphoma, and melanoma.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 0
Rotatable bonds 4
Topological polar surface area 75.58
Molecular weight 491.24
XLogP 5.09
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Cc1nnn(c1c1cnc2c(c1)n([C@H](c1ccccc1)C1CCOCC1)c1c2c2cnn(c2cc1)C)C
Isomeric SMILES Cc1nnn(c1c1cnc2c(c1)n([C@H](c1ccccc1)C1CCOCC1)c1c2c2cnn(c2cc1)C)C
InChI InChI=1S/C29H29N7O/c1-18-28(35(3)33-32-18)21-15-25-27(30-16-21)26-22-17-31-34(2)23(22)9-10-24(26)36(25)29(19-7-5-4-6-8-19)20-11-13-37-14-12-20/h4-10,15-17,20,29H,11-14H2,1-3H3/t29-/m1/s1
InChI Key BBKUPPVLTRGWDN-GDLZYMKVSA-N
References
1. Bian B, Juiz NA, Gayet O, Bigonnet M, Brandone N, Roques J, Cros J, Wang N, Dusetti N, Iovanna J. (2019)
Pancreatic Cancer Organoids for Determining Sensitivity to Bromodomain and Extra-Terminal Inhibitors (BETi).
Front Oncol, 9: 475. [PMID:31231611]
2. Yin M, Guo Y, Hu R, Cai WL, Li Y, Pei S, Sun H, Peng C, Li J, Ye R et al.. (2020)
Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction.
Nat Commun, 11 (1): 1833. [PMID:32286255]